CBC is the panel you order first. Fifty euros, 24-hour turnaround, covers the variable most likely to send you to a cardiologist before it sends you to an endocrinologist: erythrocytosis. The published TRT and AAS cardiovascular outcomes literature consistently identifies elevated haematocrit as the single most clinically actionable biomarker shift in long-term users (Ohlander et al. 2018, Sex Med Rev).
One baseline draw before the protocol, one at week 8–12. That is the minimum. The pre-cycle draw is not optional — without baseline, a week-12 result is half of a sentence.
The Mechanism Behind Testosterone-Driven Erythrocytosis
Exogenous testosterone elevates red cell mass through two convergent pathways. The first is direct stimulation of renal erythropoietin (EPO) release. The second — described mechanistically by Bachman et al. 2014 in J Gerontol — is suppression of hepcidin. Hepcidin normally sequesters iron in macrophages and intestinal enterocytes; its suppression releases stored iron for haem synthesis, removing the iron-availability brake on erythropoiesis. The combined EPO-up plus hepcidin-down signal produces a dose-dependent erythrocyte response that is steeper than EPO alone would predict.
Clinical implication: the rise is not optional, not avoidable through hydration, and not a sign of something “going wrong” — it is the expected pharmacological response. The question is not whether your HCT will rise, it is by how much, and at what threshold the cardiovascular cost outweighs the protocol benefit.
Red Blood Cell Line — Reference Frame
Hemoglobin (HGB) — 13.5–17.5 g/dL adult male reference (per Kratz & Lewandrowski, NIH Bookshelf laboratory reference intervals). At 500 mg/week testosterone, expected drift is +1–2 g/dL above baseline by week 8, plateau around week 12. Boldenone undecylenate runs steeper — +2–3 g/dL is typical, mechanism via additional direct erythropoietic action documented in case series. Above 18 g/dL the polycythaemic risk profile activates clinically; above 19 g/dL therapeutic phlebotomy is indicated regardless of cycle stage.
Hematocrit (HCT) — 38.8–50% reference. Moves in lockstep with HGB at a roughly 3:1 ratio (3 percentage points HCT per 1 g/dL HGB). 52% is the clinical action threshold cited in the Endocrine Society TRT guidelines (Bhasin et al. 2018, J Clin Endocrinol Metab); 54%+ is frank polycythaemia with documented stroke, MI, and DVT signal in the long-term TRT outcomes literature (Ohlander 2018).
Red Blood Cell count (RBC) — 4.5–5.9 million/µL. Downstream marker of the same erythropoietic process. Rarely tells you anything HGB/HCT does not, but reported by default on the panel.
Why It Matters — The Cardiovascular Mechanism
Sustained HCT above 52% increases whole-blood viscosity exponentially rather than linearly (Çinar et al. 2001, Clin Hemorheol Microcirc). At HCT 58%, plasma viscosity is approximately double the value at 48%. Higher viscosity raises shear stress on vascular endothelium, activates the coagulation cascade through endothelial mechanotransduction, and drives the prothrombotic shift documented in the bodybuilder cardiovascular mortality case series.
The risk is not theoretical. Kanayama et al. 2018, Mayo Clin Proc reviewed the cardiovascular mortality patterns in long-term AAS users and identified erythrocytosis as the consistent biomarker present at sudden cardiac death and stroke presentations across multiple cohorts. The pattern is more reliable than the lipid signal because erythrocytosis acts acutely (over weeks-to-months), while atherosclerotic risk integrates across years.
Mitigation — The Mechanical Intervention
Whole-blood donation is the first-line intervention. A 450 mL donation drops HCT by approximately 3 percentage points and resets the trajectory for 8–12 weeks. The mechanism is straightforward: removal of red cell mass, with reticulocyte response and replacement erythropoiesis taking 6–8 weeks to fully restore. US: every 56 days minimum. EU: every 3 months for males (per Établissement français du sang guidelines and equivalent national bodies).
Ferritin surveillance becomes mandatory with repeated phlebotomy. Iron stores deplete faster than the user expects, particularly in athletes with high baseline turnover. Ferritin below 30 ng/mL produces fatigue disproportionate to the HCT reduction and may paradoxically worsen subjective cycle response. Target ferritin 50–150 ng/mL; supplement when trending toward floor.
Low-dose aspirin (81 mg/day) is commonly cited for antiplatelet prophylaxis above HCT 52%. The evidence base in the AAS-specific population is limited but extrapolated from primary cardiovascular prevention trials in elevated-risk subgroups (ASCEND Study Collaborative Group 2018, NEJM). The harm-reduction calculus is favourable in high-HCT users without bleeding-risk contraindications. Gastroprotection (PPI or H2 blocker) is reasonable on chronic use.
Hydration is not a treatment, it is a measurement correction. Dehydrated draws read HCT 2–3 percentage points higher than true steady-state from hemoconcentration. 500 mL water 60 minutes before draw normalises the artefact; it does not affect true polycythaemia.
The Confounder the Standard Answer Omits — Sleep Apnea
Obstructive sleep apnea (OSA) mimics testosterone-driven HCT elevation through the identical pathway: intermittent nocturnal hypoxia drives EPO release. Users presenting with unexpectedly high HCT despite modest testosterone doses frequently have undiagnosed OSA (Hoyos et al. 2012, Eur J Endocrinol documents the bidirectional relationship between TRT and OSA severity).
Clinical signs warranting sleep-study workup before attributing HCT to the protocol: heavy snoring, daytime somnolence (Epworth score ≥10), partner-reported apneic episodes, morning headache, untreated hypertension, BMI >30. The intervention sequence is reversed for OSA-driven erythrocytosis — CPAP therapy resolves the HCT picture without dose reduction.
Platelet Line
Platelets — 150–450 thousand/µL. Most injectable AAS do not meaningfully alter platelet count. Oral 17α-alkylated compounds can transiently depress platelets through hepatic megakaryocyte effects; persistent platelets <140k on orals warrants end-of-cycle retest to verify trend rather than spot value. Stanozolol shows the strongest platelet-suppression signal in published case reports.
White Blood Cell Line
WBC total — 4.5–11.0 thousand/µL. Rarely changed by AAS. Elevated WBC usually points to infection, inflammation, or recent vaccination — unrelated to the protocol. Pre-cycle WBC elevation is reason to delay initiation until normalisation; launching a suppressive cycle on top of an immune-challenged baseline is poor sequencing.
Timing the Draw
Fasted, morning draw between 7–10 AM. Endogenous cortisol and testosterone follow circadian patterns; standardising the draw time eliminates an avoidable source of noise across longitudinal panels. For AAS specifically, draw on the lowest-concentration day of your injection schedule — trough rather than peak. Monday/Thursday injection schedule means Thursday morning draw before the shot.
No training within 48 hours pre-draw. Heavy training elevates CK, AST, and to a lesser extent ALT through skeletal-muscle release; on a CBC panel, intense recent exercise also produces transient leukocytosis through demargination.
Action Thresholds
- HCT 51–53%: hydrate, recheck monthly, consider donating at 53%.
- HCT 54%+: donate immediately, reduce dose 20–30%, retest in 6 weeks.
- HCT 58%+: donate, hold dose pending recheck, evaluate for OSA, clinical review if persistent.
- HGB 18+ g/dL: equivalent to HCT 54+ — same action.
- Platelets <140k on orals: end the oral compound early, retest in 3 weeks.
- WBC >12k pre-cycle: delay protocol initiation; investigate underlying cause.
The Trajectory Framing
The goal is not perfect numbers in isolation — it is keeping the trajectory flat across the cycle and stable across years on cruise. A haematocrit of 49 that started at 44 is a different clinical story from a haematocrit of 49 that started at 50. The first signals reactive erythropoiesis approaching threshold; the second signals a stable response within reference.
Multi-cycle longitudinal tracking is the only way the trajectory becomes legible. Rasmussen et al. 2016, J Clin Endocrinol Metab documented persistent biomarker shifts in former AAS users including erythropoietic effects that did not fully normalise across years post-cessation, suggesting that integrated exposure matters beyond any single cycle’s drift. Bloodwork without baseline is half-information; bloodwork without longitudinal tracking is informationally adjacent to no bloodwork at all.